Spruce Biosciences, Inc.(SPRB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SPRB Spruce Biosciences, Inc.

Pre-Mkt 08-10 04:42:56 EDT

46.87

+0.45

+0.97%

High47.43	Low45.88	Vol33.99K
Open47.00	D1 Closing46.42	Amplitude3.34%
Mkt Cap129.00M	Tradable Cap124.36M	Total Shares2.75M
T/O1.59M	T/O Rate1.28%	Tradable Shares2.65M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SPRB","market":"US","secType":"STK","nameCN":"Spruce Biosciences, Inc.","latestPrice":46.87,"timestamp":1786132800000,"preClose":46.42,"halted":0,"volume":33989,"delay":0,"changeRate":0.009694097371822398,"floatShares":2653399,"shares":2752300,"eps":-38.620026,"marketStatus":"Pre-Mkt","change":0.45,"latestTime":"08-10 04:42:56 EDT","open":47,"high":47.425,"low":45.875,"amount":1594388.64144,"amplitude":0.033391,"askPrice":51.45,"askSize":100,"bidPrice":39.33,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-38.620026,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1786368600000},"marketStatusCode":1,"adr":0,"listingDate":1602216000000,"exchange":"NASDAQ","adjPreClose":46.87,"postHourTrading":{"tag":"盘后","latestPrice":46.87,"preClose":46.87,"latestTime":"19:34 EDT","volume":217,"amount":10156.67,"timestamp":1786145651017,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8383899694987544,"impliedVol":0.883,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/SPRB","defaultTab":"news","newsList":[{"id":"2656376631","title":"Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.d., as Vice President, Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2656376631","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656376631?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:00","pubTimestamp":1785758401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nTUA8S3T53:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655804036","title":"Spruce Biosciences Moves Tralesinidase Alfa Into Phase 3, Putting Rare Disease Upside in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2655804036","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655804036?lang=en_us&edition=fundamental","pubTime":"2026-07-31 00:32","pubTimestamp":1785429135,"startTime":"0","endTime":"0","summary":"Spruce Biosciences, Inc. ($SPRB) announced an update on their ongoing clinical study. Spruce Biosciences, Inc. is launching a Phase 3 study called ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/spruce-biosciences-moves-tralesinidase-alfa-into-phase-3-putting-rare-disease-upside-in-focus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/spruce-biosciences-moves-tralesinidase-alfa-into-phase-3-putting-rare-disease-upside-in-focus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655816912","title":"Spruce Biosciences Files Form 3 for Chief Medical Officer Adrian W. Quartel","url":"https://stock-news.laohu8.com/highlight/detail?id=2655816912","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655816912?lang=en_us&edition=fundamental","pubTime":"2026-07-30 04:10","pubTimestamp":1785355850,"startTime":"0","endTime":"0","summary":"Spruce Biosciences files Form 3 for Chief Medical Officer Adrian W. QuartelSpruce Biosciences filed an initial Form 3 for Chief Medical Officer Adrian W. Quartel on July 29, 2026.Disclaimer:This news ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDL1vBWMy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654175650","title":"Spruce Biosciences Names Adrian Quartel Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2654175650","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654175650?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:00","pubTimestamp":1785153646,"startTime":"0","endTime":"0","summary":"Spruce Biosciences names Adrian Quartel chief medical officerSpruce Biosciences named Adrian Quartel as chief medical officer, effective today, as it targets a BLA filing for tralesinidase alfa in Q4 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nNDLb2Nl1n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZVRA","SPRB","IE00B19Z3581.USD","BK4007","IE00B19Z3B42.SGD","BK4139","BMRN","IE0002270589.USD","IE00B7SZLL34.SGD","SUPN","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654582017","title":"Spruce Biosciences Appoints Adrian Quartel, M.d., Ffpm, as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2654582017","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654582017?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:00","pubTimestamp":1785153601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUALS6LC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651114789","title":"Spruce Biosciences Initiated at Buy by B. Riley Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2651114789","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651114789?lang=en_us&edition=fundamental","pubTime":"2026-07-13 21:18","pubTimestamp":1783948680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SPRB/analyst-ratings(END) Dow Jones NewswiresJuly 13, 2026 09:18 ET","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651111529","title":"B. Riley Initiates Spruce Biosciences at Buy With $160 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2651111529","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651111529?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:27","pubTimestamp":1783945679,"startTime":"0","endTime":"0","summary":"Spruce Biosciences (SPRB) has an average rating of buy and mean price target of $149.71, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651677411","title":"Spruce Biosciences, Inc : B. Riley Initiates Coverage with Buy Rating; Target Price $160","url":"https://stock-news.laohu8.com/highlight/detail?id=2651677411","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651677411?lang=en_us&edition=fundamental","pubTime":"2026-07-13 11:13","pubTimestamp":1783912415,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nFWN43C10Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647371579","title":"Spruce Biosciences joins Russell 3000 Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2647371579","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647371579?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:15","pubTimestamp":1782735324,"startTime":"0","endTime":"0","summary":"Spruce Biosciences (SPRB) announced that it has been added as a member of the Russell 3000 Index, effective with the opening of U.S. equity markets...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spruce-biosciences-joins-russell-3000-index-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spruce-biosciences-joins-russell-3000-index-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645697024","title":"Spruce Biosciences names Agnieszka Jurecka vice president, medical affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2645697024","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645697024?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:00","pubTimestamp":1782129640,"startTime":"0","endTime":"0","summary":"Spruce Biosciences named Agnieszka “AJ” Jurecka vice president, medical affairs, as it prepares for a potential U.S. FDA decision on tralesinidase alfa.She most recently served as chief medical officer at a seed-stage gene therapy company developing CNS-directed therapies for lysosomal gene defects.Jurecka previously led rare-disease programs at CoA Therapeutics and Ultragenyx, with earlier medical affairs roles at Shire, Synageva, Aegerion, and BioMarin.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL6y6MPx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB","BK4139","BK4566","RARE","IE00B19Z3581.USD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","BMRN","IE0002270589.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645024549","title":"Spruce Biosciences Appoints Agnieszka Jurecka, M.d., Ph.d., Mph, as Vice President, Medical Affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2645024549","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645024549?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:00","pubTimestamp":1782129601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUAYKYPG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643475732","title":"Spruce Biosciences Initiated at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2643475732","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643475732?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:42","pubTimestamp":1781613720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SPRB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 16, 2026 08:42 ET (12:42 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643520383","title":"Spruce Biosciences names Eric Jordan as VP, Marketing","url":"https://stock-news.laohu8.com/highlight/detail?id=2643520383","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643520383?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:01","pubTimestamp":1781524901,"startTime":"0","endTime":"0","summary":"Spruce Biosciences named Eric Jordan vice president, marketing, as it prepares for a potential U.S. FDA approval and launch of TA-ERT.Jordan previously led marketing and launch planning for encaleret at BridgeBio.He earlier ran U.S. commercialization of Oxervate at Dompé Pharmaceuticals, helping build it into a $1 billion brand.Tina Gullotta joined as vice president, finance, corporate controller, tasked with scaling finance and reporting as Spruce moves toward commercialization.Gullotta was vice president, finance at Frontier Medicines, following senior finance roles at Sunesis Pharmaceuticals and Atara Biotherapeutics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to genera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL7QcwGm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRB","ATRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643208045","title":"Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller","url":"https://stock-news.laohu8.com/highlight/detail?id=2643208045","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643208045?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:00","pubTimestamp":1781524803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA3TPD6M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642498942","title":"Spruce Biosciences Initiated at Buy by Jones Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2642498942","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642498942?lang=en_us&edition=fundamental","pubTime":"2026-06-09 21:16","pubTimestamp":1781010960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SPRB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 09, 2026 09:16 ET (13:16 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642699432","title":"Spruce Biosciences Reports Long-Term Data for Enzyme Replacement Therapy to Treat Genetic Disease MPS IIIB","url":"https://stock-news.laohu8.com/highlight/detail?id=2642699432","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642699432?lang=en_us&edition=fundamental","pubTime":"2026-06-09 05:45","pubTimestamp":1780955100,"startTime":"0","endTime":"0","summary":"Spruce Biosciences  said late Monday its long-term data for tralesinidase alfa enzyme replacement therapy in patients with fatal genetic disease Sanfilippo Syndrome Type B or MPS IIIB, demonstrated a rapid and durable reduction of heparan sulfate non-reducing end, which is a surrogate endpoint.Data also showed relatively preserved cognitive and non-cognitive outcomes, including communication and motor skills, over a six-year period, according to a statement.These findings support the therapy's potential as the first disease-modifying treatment option, the company said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642343354","title":"Spruce Biosciences initiated with a Buy at JonesResearch","url":"https://stock-news.laohu8.com/highlight/detail?id=2642343354","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642343354?lang=en_us&edition=fundamental","pubTime":"2026-06-09 04:26","pubTimestamp":1780950396,"startTime":"0","endTime":"0","summary":"JonesResearch analyst Catherine Novack initiated coverage of Spruce Biosciences (SPRB) with a Buy rating and $135 price target The firm says its va...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spruce-biosciences-initiated-with-a-buy-at-jonesresearch-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spruce-biosciences-initiated-with-a-buy-at-jonesresearch-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642431494","title":"Spruce says long-term TA-ERT data presented at MPS Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2642431494","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642431494?lang=en_us&edition=fundamental","pubTime":"2026-06-09 04:11","pubTimestamp":1780949487,"startTime":"0","endTime":"0","summary":"Spruce Biosciences (SPRB) announced that data demonstrating the long-term benefit of tralesinidase alfa enzyme replacement therapy in patients with...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spruce-says-long-term-ta-ert-data-presented-at-mps-symposium-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spruce-says-long-term-ta-ert-data-presented-at-mps-symposium-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642313774","title":"Spruce Biosciences reports six-year tralesinidase alfa data showing sustained biomarker reductions, stabilized cognition in MPS IIIB","url":"https://stock-news.laohu8.com/highlight/detail?id=2642313774","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642313774?lang=en_us&edition=fundamental","pubTime":"2026-06-09 04:05","pubTimestamp":1780949142,"startTime":"0","endTime":"0","summary":"Spruce Biosciences reports six-year tralesinidase alfa data showing sustained biomarker reductions, stabilized cognition in MPS IIIB. Spruce Biosciences reported long-term data for tralesinidase alfa enzyme replacement therapy in Sanfilippo syndrome type B, presented June 4-7, 2026.Results included data previously presented at the 22nd Annual WORLD Symposium, extending follow-up to as long as six years.Treatment was associated with sustained disease-biomarker improvement, with cognitive function and daily functioning preserved versus declines in untreated natural history patients.Imaging and organ assessments were consistent with stabilization of disease-related changes, supporting a potential disease-modifying profile.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financia","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDLC4gpf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642431354","title":"Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (Mps Iiib) Presented at the 18TH International Mps Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2642431354","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642431354?lang=en_us&edition=fundamental","pubTime":"2026-06-09 04:05","pubTimestamp":1780949100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nTUA3BHBKF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sprucebiosciences.com","stockEarnings":[{"period":"1week","weight":0.0943},{"period":"1month","weight":-0.0588},{"period":"3month","weight":-0.1704},{"period":"6month","weight":-0.3526},{"period":"1year","weight":346.1852},{"period":"ytd","weight":-0.4619}],"compareEarnings":[{"period":"1week","weight":0.0351},{"period":"1month","weight":0.0374},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1197},{"period":"1year","weight":0.223},{"period":"ytd","weight":0.1339}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.190445},{"month":2,"riseRate":0.5,"avgChangeRate":-0.036118},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.209049},{"month":4,"riseRate":0,"avgChangeRate":-0.19428},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.048966},{"month":6,"riseRate":0.5,"avgChangeRate":-0.057688},{"month":7,"riseRate":0.5,"avgChangeRate":0.040059},{"month":8,"riseRate":0.5,"avgChangeRate":0.039502},{"month":9,"riseRate":0.4,"avgChangeRate":-0.136102},{"month":10,"riseRate":0.4,"avgChangeRate":2.105377},{"month":11,"riseRate":0.5,"avgChangeRate":0.001192},{"month":12,"riseRate":0.333333,"avgChangeRate":0.217863}],"exchange":"NASDAQ","name":"Spruce Biosciences, Inc.","nameEN":"Spruce Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Spruce Biosciences, Inc.(SPRB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Spruce Biosciences, Inc.(SPRB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Spruce Biosciences, Inc.,SPRB,Spruce Biosciences, Inc.股票,Spruce Biosciences, Inc.股票老虎,Spruce Biosciences, Inc.股票老虎国际,Spruce Biosciences, Inc.行情,Spruce Biosciences, Inc.股票行情,Spruce Biosciences, Inc.股价,Spruce Biosciences, Inc.股市,Spruce Biosciences, Inc.股票价格,Spruce Biosciences, Inc.股票交易,Spruce Biosciences, Inc.股票购买,Spruce Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Spruce Biosciences, Inc.(SPRB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Spruce Biosciences, Inc.(SPRB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}